Trial Profile
A phase I/II study of Taxol [paclitaxel], estramustine and quadramet [Samarium-153-SM-lexidronam] in patients with hormone refractory prostate cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Jul 2006
Price :
$35
*
At a glance
- Drugs Estramustine (Primary) ; Paclitaxel (Primary) ; Samarium 153 lexidronam (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jul 2006 New trial record.